Joshua F Zeidner
Overview
Explore the profile of Joshua F Zeidner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidner J, Sallman D, Recher C, Daver N, Leung A, Hiwase D, et al.
Blood
. 2025 Feb;
PMID: 40009500
Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine...
2.
Mort J, Brighton D, DiBenedetto S, Wells L, Clark S, Reid J, et al.
Eur J Haematol
. 2024 Nov;
114(3):481-494.
PMID: 39601208
Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical...
3.
Lachowiez C, Ravikumar V, Othman J, ONions J, Peters D, McMahon C, et al.
Blood
. 2024 Nov;
144(26):2788-2792.
PMID: 39486083
The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene...
4.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
5.
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, et al.
Blood
. 2024 Jul;
144(19):2033-2044.
PMID: 38996210
Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without...
6.
Bewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, et al.
Ann Hematol
. 2023 Nov;
103(1):105-116.
PMID: 38036712
Patients with myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) with hypomethylating agent failure have a poor prognosis. Myeloid-derived suppressor cells (MDSCs) can contribute to MDS progression and mediate resistance...
7.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):209-218.
PMID: 37921062
A large-scale genomic analysis of patients with -mutated myeloid disease has not been performed to date. We reviewed comprehensive genomic profiling results from 6043 adults to characterize clinicopathologic features and...
8.
Daver N, Vyas P, Kambhampati S, Al Malki M, Larson R, Asch A, et al.
J Clin Oncol
. 2023 Sep;
41(31):4893-4904.
PMID: 37703506
Purpose: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells,...
9.
Shallis R, Daver N, Altman J, Komrokji R, Pollyea D, Badar T, et al.
Lancet Haematol
. 2023 Aug;
10(9):e767-e776.
PMID: 37572683
The existence of two acute myeloid leukaemia classification systems-one put forth by WHO and one by the International Consensus Classification in 2022-is concerning. Although both systems appropriately move towards genomic...
10.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Blood Cancer J
. 2023 Jun;
13(1):96.
PMID: 37365170
No abstract available.